Protease Inhibitors May Finally Crack Cancer’s Drug Resistance Problem

Chemotherapy saves countless lives, yet one of oncology’s most stubborn enemies remains the ability of cancer cells to shrug off the very drugs designed to kill them. A new review published in Molecular Biology Reports by Gino A. Kurian of SASTRA Deemed University examines an underappreciated player in this drama: proteases, the enzymes that cut other proteins apart. Far from being mere housekeeping enzymes, proteases emerge from the analysis as active architects of chemoresistance, shaping everything from drug transport and tumor architecture to cell death signaling itself.

The review synthesizes mechanistic evidence across several protease families, including matrix metalloproteinases, cathepsins, ubiquitin-specific proteases, proteasome components, and mitochondrial proteases. Each family contributes to therapeutic escape through distinct routes. Matrix metalloproteinases, for example, remodel the extracellular matrix, physically altering the tumor microenvironment in ways that limit drug penetration and support invasion. Cathepsins, particularly cathepsin B, are highly expressed in pancreatic cancer stem-like cells and have been linked to poorer surgical outcomes, positioning them as both biomarkers and potential drug targets.

One of the most technically interesting threads involves ubiquitin-specific proteases, enzymes that remove ubiquitin tags from proteins and thereby rescue them from degradation. By stabilizing pro-survival proteins, these deubiquitinases can blunt the effect of drugs that rely on triggering apoptotic pathways. Ubiquitin-specific protease 7 has attracted particular attention as a target for overcoming drug resistance, and inhibitors of these enzymes are being explored as a route to re-sensitize tumors that have learned to survive chemotherapy.

The proteasome itself, the cellular machine that degrades tagged proteins, represents another protease-centered axis of resistance. Proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib have already achieved clinical success, most notably in multiple myeloma, where the phase 3 ENDEAVOR trial demonstrated the benefit of carfilzomib combined with dexamethasone over bortezomib-based therapy. These agents prove that protease-directed therapy can work in the clinic, even if their greatest successes have come in hematological malignancies rather than solid tumors.

Perhaps the most striking clinical story involves HIV protease inhibitors, drugs originally designed for a completely different disease. Nelfinavir, saquinavir, ritonavir, lopinavir, and indinavir have all shown anticancer activity in various settings. Nelfinavir inhibits proteasome function and induces endoplasmic reticulum stress in glioma cells, while ritonavir suppresses survivin in lung cancer cells. Clinical trials have tested nelfinavir alongside chemoradiation in locally advanced pancreatic cancer, from early phase 1 studies through the phase 2 ARCII trial and the more recent SCALOP-2 trial, and a phase 3 protocol known as NELCER is evaluating nelfinavir with chemoradiation and brachytherapy in cervical cancer. A phase 2 trial also reported clinical efficacy of indinavir combined with chemotherapy for advanced classic Kaposi sarcoma in elderly patients.

Why, then, has broad-spectrum protease inhibition largely disappointed in oncology? The review identifies several converging reasons. Many inhibitors lack sufficient isoform selectivity, hitting multiple protease family members with different, sometimes opposing, roles. Cancer cells compensate through parallel signaling pathways, so blocking one route of resistance simply reroutes the traffic. Patient stratification has often proceeded without biomarkers that identify who actually carries the relevant protease dependency, and pharmacodynamic validation, confirming that the drug truly engaged its target in the tumor, has frequently been missing. The result is a persistent gap between strong biological rationale and limited clinical success.

The mechanistic landscape is further complicated by the interplay between proteases and other hallmarks of resistance. Proteases regulate epithelial-mesenchymal transition, the program by which cancer cells become more invasive and drug-tolerant, and they help maintain cancer stem cell populations that seed relapse. They also intersect with signaling cascades such as PI3K/AKT/NF-κB and MAPK pathways, with oxidative stress responses, and with autophagy, all of which have been implicated in resistance to agents ranging from gemcitabine and doxorubicin to platinum drugs and taxanes. Targeting a single enzyme family without accounting for this network risks repeating the failures of earlier broad-spectrum matrix metalloproteinase inhibitors, such as marimastat, which showed no benefit in a randomized trial of glioblastoma patients.

Emerging strategies aim to escape this trap by being context-specific rather than indiscriminate. Biomarker-guided patient selection seeks to treat only those tumors whose proteomic profiles reveal genuine protease dependencies. Rational combination therapy pairs protease inhibitors with conventional chemotherapeutics in ways suggested by systematic drug combination screens, such as the large-scale effort published in Nature that mapped effective combinations in breast, colon, and pancreatic cancer cell lines. Advanced delivery platforms add another layer of precision: protease-activated prodrugs release their payload only where specific proteases are active, and nanoparticle systems, including matrix metalloproteinase-responsive nanoparticles and thermosensitive liposomes carrying MMP inhibitors, concentrate inhibitory activity within the tumor microenvironment while sparing healthy tissue.

The review also highlights tools that could sharpen the field’s aim. Proteomic profiling, integrated with functional validation, may identify which proteases a given tumor truly depends upon, moving treatment decisions from empirical enzyme blockade toward mechanism-driven intervention. Activity-based probes, already evaluated preclinically for intraoperative imaging of esophageal cancer, exemplify how protease activity can be visualized directly, potentially guiding both diagnosis and surgical margins. Natural product-derived inhibitors, such as the Bowman-Birk family of protease inhibitors, continue to be explored as sources of multifunctional lead compounds.

Kurian’s synthesis ultimately delivers a measured but forward-looking message. Proteases are deeply woven into the machinery of chemoresistance, modulating drug transport, extracellular matrix remodeling, epithelial-mesenchymal transition, apoptosis, and pro-survival signaling across multiple malignancies. The clinical record shows both the promise of the approach, through proteasome inhibitors and repurposed HIV protease inhibitors, and its pitfalls, through failed broad-spectrum trials. The path forward, the review argues, lies in precision: matching the right protease target to the right tumor, validated by biomarkers and delivered by smart drug platforms. Whether that precision can be achieved at scale remains the decisive question, and the author is careful to note that further clinical validation is still required before protease inhibition can fulfill its promise of breaking the barriers of chemoresistance in cancer.

Subject of Research: The role of protease families in cancer chemoresistance and strategies for protease-targeted therapy

Article Title: Protease inhibition: breaking the barriers of chemoresistance in cancer

Article References: Kurian, G. A. (2026). Protease inhibition: breaking the barriers of chemoresistance in cancer. Molecular Biology Reports, 53(1), Article 1548. https://doi.org/10.1007/s11033-026-12659-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12659-0

Keywords: chemoresistance, proteases, matrix metalloproteinases, cathepsins, ubiquitin-specific proteases, proteasome inhibitors, HIV protease inhibitors, tumor microenvironment, biomarker-guided therapy, nanoparticle drug delivery, cancer stem cells, nelfinavir